Document is current
Any future updates will be listed below
-
Authors
Wong, Chee Wai
Wong, Edmund
Metselaar, Josbert M.
Storm, Gert
Wong, Tina T. https://orcid.org/0000-0003-1429-2895
-
Funding
Funding for this research was provided by:
National Medical Research Council, Singapore (NMRC/Fellowship/0045/2017)
National Health Innovation Centre, Singapore (NHIC-I2D-1808207)
- License Information
-
More Information
Article History
Accepted: 15 January 2021
First Online: 10 February 2021
Declarations
:
: Chee Wai Wong: Novartis, Singapore (Honoraria), Bayer, Singapore (Honoraria), Roche, Singapore (Honoraria), IP and patent holder for liposomal prednisolone phosphate; Edmund Wong: None; Josbert M. Metselaar: Enceladus, Netherlands (CEO), IP and patent holder for liposomal prednisolone phosphate; Gert Storm: IP and patent holder for liposomal prednisolone phosphate; Tina T Wong: IP and patent holder for liposomal prednisolone phosphate.
: The study protocol was approved by the SingHealth Centralised Institutional Review Board (protocol number R1600/99/2018).
: All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000 (5). Informed consent was obtained from all patients for being included in the study.
: Informed consent was obtained from all participants.
: All authors give consent for publication.
